Actively Recruiting
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Led by The University of Texas Health Science Center at San Antonio · Updated on 2026-04-20
150
Participants Needed
1
Research Sites
580 weeks
Total Duration
On this page
Sponsors
T
The University of Texas Health Science Center at San Antonio
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Create a living biobank of PDOs from Stage I-III lung cancer patients.
CONDITIONS
Official Title
Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Read, consented to and signed the IRB-approved informed consent form before any study procedure
- Diagnosed with lung cancer, lung mass, or lymphadenopathy requiring systemic treatment or tumor resection as standard care
- Any clinical stage of lung cancer
- Adult patients 18 years or older
- Able and willing to complete a questionnaire on environmental/occupational exposures and smoking/alcohol history
You will not qualify if you...
- Patient unable to meet study requirements as determined by the treating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UT Health San Antonio, M.D. Anderson Cancer Center
San Antonio, Texas, United States, 78229
Actively Recruiting
Research Team
J
Josephine Taverna, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here